. 2023 Sep 5;28(6):849–859. doi: 10.1007/s12192-023-01376-3

Table 4.

Effect of ADR and/or NAC treatment on liver MtrnL immunoreactivities and ELISA levels

	Control	NAC	ADR	ADR + NAC	p
MtrnL (IHC)	1.20 ± 0.11^b	1.32 ± 0.12	1.97 ± 0.20^a	1.54 ± 0.23	= 0.026
MtrnL (ng/ml)	3.48 ± 0.12^b	3.19 ± 0.10^b	4.59 ± 0.11^a	3.66 ± 0.09^b	< 0.001

Control

NAC

ADR

ADR + NAC

MtrnL (IHC)

1.20 ± 0.11^b

1.32 ± 0.12

1.97 ± 0.20^a

1.54 ± 0.23

= 0.026

MtrnL

(ng/ml)

3.48 ± 0.12^b

3.19 ± 0.10^b

4.59 ± 0.11^a

3.66 ± 0.09^b

< 0.001

Values are presented as mean ± standard error. ^a: Compared with the control group (p < 0.05), ^b: Compared with the ADR group (p < 0.05). ADR: Adriamycin; NAC: N-Acetylcysteine, MtrnL: Meteorin-Like, IHC; Immunohistochemical staining